A to Z / Metabolic / weight loss
CagriSema
Also known as cagrilintide + semaglutide.
Best known for The combination aiming at tirzepatide
Evidence★★★☆☆
Safety dataModerately characterised
Route Weekly injection
United StatesInvestigational
AustraliaNot approved
as at 16 September 2026
What it is
CagriSema is a fixed combination of cagrilintide (a long-acting amylin analogue) and semaglutide (a GLP-1 agonist), delivered in one weekly injection. It is a late-stage investigational medicine: phase-3 results have been reported, and it is not approved anywhere yet.
What the full entry covers
The book carries the rest of this entry:
- Where the research stands, with every claim cited
- What people commonly ask, and what the research shows so far
- Dosing in four labelled bands, described and not recommended
- Side effects, serious risks, cautions and interactions
- Questions to discuss with your doctor
- How it compares with Cagrilintide, Semaglutide, Tirzepatide, Retatrutide
Related entries
A certificate of analysis tells you what is in a vial. The evidence rating above tells you whether the compound has been shown to work in humans. Neither answers the other's question. How to read a certificate of analysis.
This page describes what is known and not known about CagriSema. It is not medical advice and not a recommendation to use it.